I have been thinking lately that L-tryptophan and 5-HTP are potentially bad for cognition.
Pronounced cognitive deficits following an intravenous L-tryptophan challenge in first-degree relatives of bipolar patients compared to healthy controls.
Sobczak S, Honig A, Schmitt JA, Riedel WJ.
Brain and Behavior Institute, Department of Psychiatry and Neuropsychology, Universiteit Maastricht, The Netherlands.
Cognitive impairment has repeatedly been described in bipolar disorders (BD). Serotonin (5-hydroxytryptophan; 5-HT) is possibly involved in these cognitive processes, more particularly in executive functions, learning, memory, and attention. The aim of this study was to investigate serotonergic vulnerability and its relation to cognitive functioning in healthy first-degree relatives of BD patients. We investigated the effects of an intravenous (i.v.) tryptophan (Trp) challenge and placebo on cognitive performance in 30 healthy first-degree relatives of bipolar patients (FH) and 15 matched controls in a double-blind crossover design. A distinction was made between relatives of type I BD patients (FH I) and type II BD patients (FH II). Performances on planning, memory, attention, and psychomotor tasks were assessed 3 h after Trp infusion. After Trp, planning and attention were impaired in FH subjects but not in controls. Independent of Trp, FH subjects showed cognitive deficits on memory, focused and divided attention, and psychomotor performance. FH I subjects showed more pronounced cognitive impairments then FH II and controls. In all groups, Trp impaired memory and psychomotor performance significantly. In conclusions, cognitive deficits in FH following Trp may reflect a central 5-HT vulnerability in frontal brain areas. Independent of Trp, cognitive deficits in FH provide evidence for a trait marker for BD.
PMID: 12655316 [PubMed - indexed for MEDLINE]
And this from Wikipedia (oh ya)
Kynurenic acid (KYNA) is a product of the normal metabolism of amino acid L-tryptophan. It has been shown that kynurenic acid possesses neuroactive activity. It acts as an antiexcitotoxic and anticonvulsant, most likely through acting as an antagonist at excitatory amino acid receptors. Because of this activity, it may influence important neurophysiologic and neuropathologic processes. As a result, kynurenic acid has been considered for use in therapy in certain neurobiological disorders. Conversely, increased levels of kynurenic acid have also been linked to certain pathological conditions.
Kynurenic acid was discovered in 1853 by the German chemist Justus von Liebig in dog urine.[1]
It is formed from L-kynurenine in a reaction catalyzed by the enzyme kynurenine—oxoglutarate transaminase.
Contents
[hide]
* 1 Mechanism of action
* 2 Role in disease
* 3 See also
* 4 References
* 5 External links
Mechanism of action
KYNA was found to act on three receptors:
* As a noncompetitive antagonist at glycine site of the NMDA receptor.
* As an antagonist of α7 nicotinic acetylcholine receptor. This action is contrary to another tryptophan metabolite, 5-hydroxyindoleacetic acid.[2]
* As a ligand for G protein-coupled receptor GPR35.[3]
Role in disease
High levels of kynurenic acid have been identified in patients suffering from tick-borne encephalitis, schizophrenia and HIV-related illnesses. In all these situations increased levels were associated with confusion and psychotic symptoms. Kynurenic acid acts in the brain as a glycine-site NMDAr antagonist, key in glutamatergic neurotransmission system, which is thought to be involved in the pathophysiology and pathogenesis of schizophrenia.
A kynurenic acid hypothesis of schizophrenia has been proposed in 2007,[4][5] based on its action on midbrain dopamine activity and NMDArs, thus linking dopamine hypothesis of schizophrenia with the glutamate hypothesis of the disease.
High levels of kynurenic acid have been identified in human urine in certain metabolic disorders, such as marked pyridoxine deficiency and deficiency/absence of kynureninase.
Simply put, the more of the tryptophan metabolite kynurenic acid floating around in your body the more antagonism on the a7 nicotinic acetylcholine receptor, glycine site of the NMDA receptor, and enhanced risk of certain metabolic disorders.
I remember when I used to take 5-HTP, it would make me feel good yet dumb at the same time with a negatively affected memory and thinking capabilities. It all makes sense now. I also eat a natural turkey sandwich daily which I feel droggy afterwards due to the l-tryptophan. Maybe it isn't the increase of serotonin that makes you feel dumb but the increase in its metabolite kynurenic acid????? I believe so.
Edited by luv2increase, 30 July 2008 - 05:42 PM.